Report License

$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off

Order Review

Respiratory Syncytial Virus Therapeutics Market – By Drugs Type (Palivizumab, Ribavirin, Motavizumab), Route of administration (Oral, Injectable, Intranasal), Patient Type (Adult, Pediatric), Distribution Channel & Forecast, 2024 – 2032

Report ID: GMI9184
Selected License: $8,350
Discount: $2,505
Order Total: $5,845

Need assistance?

Call us or write to us:

What You Get?

Billing Information

Payment Method


creditCardImage
Top